The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?

Targeted Oncology

Volumn 11, Issue 5, 2016, Pages 593-603

  Puzzoni, Marco ^a   Silvestris, Nicola ^b   Leone, Francesco ^c   Giampieri, Riccardo ^d   Faloppi, Luca ^d   Demurtas, Laura ^a   Dell’Aquila, Emanuela ^e   Marino, Donatella ^c   Brunetti, Oronzo ^b   Garattini, Silvio Ken ^f   Ongaro, Elena ^f   Astara, Giorgio ^a   Orgiano, Laura ^a   Aprile, Giuseppe ^f   Santini, Daniele ^e   Scartozzi, Mario ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AVELUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DNA VACCINE; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

BILIARY TRACT TUMOR; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CELL THERAPY; COLORECTAL TUMOR; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOREGULATION; LIVER CELL CARCINOMA; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH TUMOR; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY;

EID: 84968627047     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-016-0437-6     Document Type: Review

References (107)

1. Burnet FM. The concept of immunological surveillance. Prog Exp tumour Res. 1970;13:1–27.
2. Thomas L. Cellular and humoral aspects of the hypersensitive states. In: Lawrence S, editor. MD, New York: Paul B. Hoeber, Inc.; 1959. 667 pp.
3. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immuno-surveillance to tumour escape. Nat Immunol. 2002;3:991–8.
4. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with metaanalysis. Br J Cancer. 2011;105(1):93–103.
5. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66.
6. Deschoolmeester V, Baay M, Van Marck E, et al. tumour infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010;11:19.
7. Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–51.
8. Galon J, Costes A. Type, density, and location of immune cells within human colorectal tumours predict clinical outcome. Science. 2006;313(5795):1960–4.
9. Gabitass RF, Annels NE, Stocken DD, et al. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011;60(10):1419–30.
10. Mundy-Bosse BL, Young GS, Bauer T, et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon alpha signaling in CD4+ T cells from patients with GI malignancy. Cancer Immunol Immunother. 2011;60(9):1269–79.
11. Chen W, Perruche S, Li J. CD4+ CD25+ T regulatory cells and TGFbeta in mucosal immune system: the good and the bad. Curr Med Chem. 2007;14(21):2245–9.
12. Yamamoto T, Yanagimoto H, Satoi S, et al. Circulating CD4+ CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas. 2012;41:409–15.
13. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumour immunity. Curr Opin Immunol. 2012;24:207–12.
14. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41–53.
15. Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumour cells with PD-1 on tumour specific T cells as a mechanism of immune evasion: Implications for tumour immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.
16. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
17. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumours with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.
18. Kim WK, Park M, Kim YJ, et al. Identification and selective degradation of neopeptide-containing truncated mutant proteins in the tumours with high microsatellite instability. Clin Cancer Res. 2013;19:3369–82.
19. Tiegs G, Lohse AW. Immune tolerance: what is unique about the liver. J Autoimmun. 2010;34(1):1–6.
20. Knolle P, Schlaak J, Uhrig A, et al. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol. 1995;22:226–9.
21. Bissell DM, Wang SS, Jarnagin WR, et al. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest. 1995;96:447–55.
22. Kassel R, Cruise MW, Iezzoni JC, et al. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology. 2009;50:1625–37.
23. Okazaki T, Maeda A, Nishimura H, et al. PD-1immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase2 to phosphotyrosine. Proc Natl Acad Sci USA. 2001;98:13866–71.
24. Bertino G, Demma S, Ardiri A, et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469.
25. Miamen AG, Dong H, Roberts LR. Immunotherapeutic approaches to hepatocellular carcinoma treatment. Liver Cancer. 2012;1:226–37.
26. Moorman JP, Wang JM, Zhang Y, et al. Tim-3 pathway controls regulatory and effector T cell balance during hepatitis C virus infection. J Immunol. 2012;189:755–66.
27. Zhang HH, Mei MH, Fei R, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. J Viral Hepat. 2010;17:34–43.
28. Li T, Yang Y, Hua X, et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett. 2012;318:154–61.
29. Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132:2328–39.
30. Gnoni A, Santini D, Scartozzi M, et al. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015;27:1–13.
31. Chang MH. Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res. 2009;181:85–94.
32. Hong YP, Li ZD, Prasoon P, et al. Immunotherapy for hepatocellular carcinoma: from basic research to clinical use. World J Hepatol. 2015;7(7):980–92.
33. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. JCO. 2015.
34. Sangro B, Gomez-Martin C, De la Mata M, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81–8.
35. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumour activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 33, 2015 (Suppl; abstract no. LBA101)
36. Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N. Hepatocellular carcinoma serum markers. Semin Oncol. 2012;39(4):410–33.
37. Bertino G, Shirin D, Ardiri A, et al. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. BioMed Res Int. 2014;doi:10.1155/2014/203693
38. Toro A, Ardiri A, Mannino M, Arcerito MC, Mannino G, Palermo F, et al. Effect of pre- and post-treatment α-fetoprotein levels and tumour size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. BMC Surg. 2014;14:40.
39. Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, et al. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9(10):1533–48.
40. Butterfield LH, Ribas A, Meng WS, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9:5902–8.
41. Sawada Y, Yoshikawa T, Nobuoka D, et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res. 2012;18:3686–96.
42. Greten TF, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209.
43. Cai XY, Gao Q, Qiu SJ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:293–301.
44. Iwashita Y, Tahara K, Goto S, et al. A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer. Cancer Immunol Immunother. 2003;52:155–61.
45. Ladhams A, Schmidt C, Sing G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous tumour-pulsed dendritic cells. J Gastroenterol Hepatol. 2002;17:889–96.
46. Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumour lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49(1):124–32.
47. Safran H, Charpentier KP, Kaubisch A, et al. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015;38(1):1–4.
48. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006;18(4):391–8.
49. Tsuchiyama T, Nakamoto Y, Sakai Y, et al. Prolonged, NK cell-mediated antitumour effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol. 2007;178:574–83.
50. Zerbini A, Pilli M, Laccabue D, et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology. 2010;138(5):1931–42.
51. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol. 2002;116(1):78–86.
52. Yelei G, Weidong H. Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Clin J Cancer. 2015;34:6.
53. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumour immunity. J Transl Med. 2013;11:83.
54. Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41(1):36–41.
55. Pan K, Li YQ, Wang W, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20(13):4305–11.
56. Lee JH, Lee JH, Lim YS, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148(7):1383–91.e6.
57. Ma Y, Xu YC, Tang L, et al. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012;1:11.
58. Li X, Dai D, Song X, et al. A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2014;38:583–91.
59. Le DT, Uram JN, Wang H, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 34, 2016 (Suppl 4S; abstract 195).
60. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. First American cancer society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52:6735–40.
61. Correa P. Helicobacter Piloryi and gastric carcinogenesis. Am J Surg Pathol. 1995;19 Suppl 1:S37–43.
62. Keunwwook L, Heyekyung H, Ki TN. Immune response and the tumour microenvironment: How they communicate to regulate gastric cancer. Gut Liver. 2014;8:131–9.
63. Matsueda S, Graham DY. Immunotherapy in gastric cancer. World J Gastroenterol. 2014;20(7):1657–66.
64. Kono K et al. Prognostic significance of adoptive immunotherapy with tumour-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clin Cancer Res. 2002;8:1767–71.
65. Jiang J et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. 2006;26:2237–42.
66. Jiang JT et al. Increasing the frequency of CIK cells adoptive immunotherapy may increase risk of death in gastric cancer patients. World J Gastroenterol. 2010;16:6155–62.
67. Masuzawa T et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012;41:1297–304.
68. Muro K et al. LBA15 – A phase 1b study on pembrolizumab (Pembro; MK-3475) in patients with advanced gastric cancer. Ann Oncol. 2014;25(5):1–41.
69. Fuchs C et al. Pembrolizumab (MK-3475) for patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: The phase 2 KEYNOTE-059 study [abstract no. P-105]. Ann Oncol. 2015;26(Suppl 4):iv29.
70. https://clinicaltrials.gov (NCT02370498). Accessed 14 Aug 2015.
71. Ohtsu A et al. Pembrolizumab (MK-3475) versus Paclitaxel as second-line therapy for advanced gastric and gastroesofageal junction (GEJ) adenocarcinoma: Randomized, open label, phase 3 KEYNOTE-061 study [abstract no. P-106]. Ann Oncol. 2015;26(Suppl 4):iv29–30.
72. https://clinicaltrials.gov (NCT02267343). Accessed 14 Aug 2015.
73. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumour cells. Cancer Immunol Res October 2015; 3:1148–57.
74. Gulley JL, Spigel D, Kelly K, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase Ib, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol 33, 2015 (Suppl; abstract no. 8034).
75. Yamada Y, Nishina T, Iwasa S, et al. A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. J Clin Oncol 33, 2015 (Suppl; abstract no. 4047).
76. ClinicalTrials.gov https://clinicaltrials.gov (NCT01772004). Accessed 14 Aug 2015.
77. Melero I, Berman DM, Aznar MA, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nature. 2015;15(8):457–72.
78. Calon A, Espinet E, Palomo-Ponce S. Dependency of colorectalcancer on a TGF-beta-drivenprogramme in stromalcells for metastasisinitiation. Cancer Cell. 2012;22(5):571–84.
79. Wang K, Kyoung MK, Di Caro G, et al. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumourigenesis. Immunity. 2014;41:1052–63.
80. Abu-Remaileh M, Bender S, Raddatz G, et al. Chronic inflammation induces a novel epigenetic program that is conserved in intestinal adenomas and in colorectal cancer. Cancer Res. 2015;75(10):2120–30.
81. Dennis KL, Wang Y, Blatner NR, et al. Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10 producing T-cells. Cancer Res. 2013;73(19):5905–13.
82. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66.
83. Katz SC, Bamboat ZM, Maker AV, et al. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013;20:946–55.
84. Reissfelder C, Stamova S, Gossmann C, et al. tumour-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. J Clin Invest. 2015;125(2):739–51.
85. Lee WS, Kang M, Baek JH, et al. Clinical impact of tumour-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 2013;20(2):697–702.
86. Sandel MH, Speetjens FM, Menon AG, et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol. 2005;42:541–6.
87. Szkandera J, Pichler M, et al. The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. Am J Surg. 2014;208(2):210–4.
88. Chen ZY, Raghav K, Lieu CH, et al. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015;112:1088–97.
89. Rooney MS, Shukla SA, Wu CJ, et al. Molecular and genetic properties of tumours associated with local immune cytolytic activity. Cell. 2015;160:48–61.
90. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2014;5(1):43–51.
91. Maby P, Tougeron D, Hamieh M, et al. Correlation between density of CD8+ T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 2015;75(17):3446–55.
92. Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T cell responses despite anti- adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother. 2013;62(8):1293–301.
93. Pernot S, Terme M, Voron T, et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol. 2014;20(14):3738–50.
94. Carnevale-Schianca F, Cignetti A, Capaldi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumour-specific T cells directed to a tumour-associated antigen are generated in vivo during GVHD. Blood. 2006;107(9):3795.
95. Curtis NJ, Primrose JN, Thomas GJ, et al. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. Eur J Surg Oncol. 2012;38:889–96.
96. Yang X, Zhang X, Mortenson ED, et al. Cetuximab-mediated tumour regression depends on innate and adaptive immune responses. Mol Ther. 2013;21:91–100.
97. Barth Jr RJ, Fischer DA, Wallace PK, et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumour-specific immune responses are associated with improved survival. Clin Cancer Res. 2010;16(22):5548–56.
98. Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting Carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–6.
99. Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective re- induction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013;19(2):462–8.
100. Tabernero J, Powderly H D, Hamid O, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, Gastric cancer (GC), SCCHN, or other tumours. J Clin Oncol. 2013;31 (Suppl; abstract no. 3622).
101. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330.
102. Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumours. J Exp Med. 2015;212(2):139–48.
103. Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33 (Suppl 3; abstract no. 704).
104. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or Monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
105. Tesniere A, Schlemmer F, Boige V, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene. 2010;29:482–91.
106. Venturelli S, Berger A, Weiland T, et al. Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2’-deoxycytidine in solid tumours. Mol Cancer Ther. 2013;12(10):2226–36.
107. Maeda K, Hazama S, Tokuno K, et al. Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumour immunity. Anticancer Res. 2011;31(12):4569–74.